الفهرس 
Acute lymphoblastic leukemiaOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Background: Vimentin (VIM), a major component of type III intermediate filament (IF) protein, is encoded by the VIM gene and is expressed in endothelial and other mesenchymal cells. VIM is instrumental in vital physiological and pathological processes, such as adhesion, migration, cell signaling, inflammation, neurite extension, and vascularization
Aim of the Work: This study aimed at measurement of serum vimentin level in the peripheral blood of Egyptian patients with acute lymphoblastic leukemia and correlating it with clinical outcome and prognosis of the disease.
Patients and Methods: 40 Newly diagnosed acute lymphoblastic leukemia (ALL) adult patients were recruited at the hemato-oncology department, Ain Shams University Hospital. They were matched to a group of 20 healthy volunteers and both groups gave written informed consents for the withdrawal and use of samples for research purposes in accordance with the 18th World Medical Association Assembly (Declaration of Helsinki, 1964) and all its future amendments. Approval of the local ethical committee was obtained. All patients were followed up for one year
Results: In this study, a total number of 60 subjects have been recruited from the Clinical Hematology Unit; Internal Medicine Department, Ain Shams University Hospitals. They were divided into 40 newly diagnosed adult acute lymphoblastic leukemia patients and 20 healthy controls of matched age and sex..
Conclusion: We concluded that vimentin is overexpressed in acute lymphoblastic leukemia patients. We recommend further study on larger cohort to emphasize our conclusion. Also to further studies are needed to prove its role as a prognostic factor. We recommend further research utilizing vimentin as potential therapeutic target.,